keyword
MENU ▼
Read by QxMD icon Read
search

'Hodgkin lymphoma'

keyword
https://www.readbyqxmd.com/read/29474096/theranostic-radiopharmaceuticals-established-agents-in-current-use
#1
James R Ballinger
Although use of the term "theranostic" is relatively recent, the concept goes back to the earliest days of nuclear medicine, with the use of radioiodine for diagnosis and therapy of benign and malignant thyroid disease being arguably the most successful molecular radiotherapy in history. A diagnostic scan with123 I-,124 I-, or a low activity of131 I-iodide is followed by therapy with high activity131 I-iodide. Similarly, adrenergic tumours such as phaeochromocytoma and neuroblastoma can be imaged with123 I-metaiodobenzylguanidine (MIBG) and treated with131 I-MIBG...
February 23, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29473436/nivolumab-in-the-treatment-of-microsatellite-instability-high-metastatic-colorectal-cancer
#2
Amir Mehrvarz Sarshekeh, Michael J Overman, Scott Kopetz
Nivolumab is a PD-1 inhibitor approved for the use in treatment of multiple tumor types (such as melanoma, non-small-cell lung cancer, renal cell carcinoma, urothelial cancer and Hodgkin's lymphoma). In July 2017, the US FDA granted accelerated approval of this agent for the treatment of metastatic colorectal cancer patients whose tumor harbors deficient mismatch repair, or microsatellite-instability high and have progressed on conventional chemotherapy. In this review, we will discuss the use, efficacy, and safety of this agent in microsatellite-instability high metastatic colorectal cancer...
February 23, 2018: Future Oncology
https://www.readbyqxmd.com/read/29473431/enhancer-of-zeste-homolog-2-ezh2-inhibitors
#3
Nitya Gulati, Wendy Béguelin, Lisa Giulino-Roth
Dysregulation of the histone methyltransferase EZH2 plays a critical role in the development of a variety of malignancies including B-cell lymphomas. As a result, a series of small molecule inhibitors of EZH2 have been developed and studied in the pre-clinical setting. Three EZH2 inhibitors: tazemetostat (EPZ-6438), GSK2816126 and CPI-1205 have moved into phase I/phase II clinical trials in patients with non-Hodgkin lymphoma and genetically defined solid tumors. Early data from the tazemetostat trials indicate an acceptable safety profile and early signs of activity in diffuse large B-cell lymphoma and follicular lymphoma, including patients with EZH2 wild-type and mutant tumors...
February 23, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29473332/chromosomal-abnormality-variation-detected-by-g-banding-is-associated-with-prognosis-of-diffuse-large-b-cell-lymphoma-treated-by-r-chop-based-therapy
#4
Yoshimi Mizuno, Taku Tsukamoto, Eri Kawata, Nobuhiko Uoshima, Hitoji Uchiyama, Isao Yokota, Saori Maegawa, Tomoko Takimoto, Kazuna Tanba, Yayoi Matsumura-Kimoto, Saeko Kuwahara-Ota, Yuto Fujibayashi, Mio Yamamoto-Sugitani, Yoshiaki Chinen, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki, Tsutomu Kobayashi, Junya Kuroda
Diffuse large B-cell lymphoma (DLBCL), which is the most prevalent disease subtype of non-Hodgkin lymphoma, is highly heterogeneous in terms of cytogenetic and molecular features. This study retrospectively investigated the clinical impact of G-banding-defined chromosomal abnormality on treatment outcomes of DLBCL in the era of rituximab-containing immunochemotherapy. Of 181 patients who were diagnosed with DLBCL and treated with R-CHOP or an R-CHOP-like regimen between January 2006 and April 2014, metaphase spreads were evaluable for G-banding in 120...
February 23, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29472617/whole-genome-diversity-of-inherited-chromosomally-integrated-hhv-6-derived-from-healthy-individuals-of-diverse-geographic-origin
#5
Marco Telford, Arcadi Navarro, Gabriel Santpere
Human herpesviruses 6-A and -B (HHV-6A, HHV-6B) are ubiquitous in human populations worldwide. These viruses have been associated with several diseases such as multiple sclerosis, Hodgkin's lymphoma or encephalitis. Despite of the need to understand the genetic diversity and geographic stratification of these viruses, the availability of complete viral sequences from different populations is still limited. Here, we present nine new inherited chromosomally integrated HHV-6 sequences from diverse geographical origin which were generated through target DNA enrichment on lymphoblastoid cell lines derived from healthy individuals...
February 22, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29471300/yttrium-90-ibritumomab-tiuxetan-zevalin%C3%A2-radioimmunotherapy-after-cytoreduction-with-eshap-chemotherapy-in-patients-with-relapsed-follicular-non-hodgkin-lymphoma-final-results-of-a-phase-ii-study
#6
Soham D Puvvada, José M Guillén-Rodríguez, Jessica Yan, Lora Inclán, Kara Heard, Xavier I Rivera, Faiz Anwer, Daruka Mahadevan, Jonathan H Schatz, Daniel O Persky
BACKGROUND: Radioimmunotherapy (RIT) is effective in treating relapsed/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan (Zevalin®) would result in durable remissions by eliminating minimal residual disease after cytoreduction. METHODS: Patients with FL received 2 cycles of ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) every 28 days, followed by Zevalin 4-6 weeks later if there was no disease progression and bone marrow biopsy showed < 25% involvement...
February 22, 2018: Oncology
https://www.readbyqxmd.com/read/29470615/pre-dosing-with-lilotomab-prior-to-therapy-with-177-lu-lilotomab-satetraxetan-significantly-increases-the-ratio-of-tumor-to-red-marrow-absorbed-dose-in-non-hodgkin-lymphoma-patients
#7
Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, Jostein Dahle, Anne C T Martinsen, Harald Holte, Arne Kolstad
PURPOSE: 177 Lu-lilotomab satetraxetan is a novel anti-CD37 antibody radionuclide conjugate for the treatment of non-Hodgkin lymphoma (NHL). Four arms with different combinations of pre-dosing and pre-treatment have been investigated in a first-in-human phase 1/2a study for relapsed CD37+ indolent NHL. The aim of this work was to determine the tumor and normal tissue absorbed doses for all four arms, and investigate possible variations in the ratios of tumor to organs-at-risk absorbed doses...
February 22, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29469767/eosinophilic-infiltrate-resembling-eosinophilic-cellulitis-wells-syndrome-in-a-patient-with-mycosis-fungoides
#8
Drew A Emge, Daniel J Lewis, Phyu P Aung
Mycosis fungoides (MF) is a T-cell, non-Hodgkin lymphoma that primarily involves the skin. Extracutaneous involvement, such as in the parotidgland, is characteristic of end-stage disease. Eosinophilic cellulitis, or Wells syndrome, is a rare inflammatory dermatitis that involves a dermal infiltrate of eosinophils. We report a case of an 80-year-old man with a long-standing diagnosis of stage IIB MF who acutely developed parotid gland involvement and marked hypereosinophilia that most likely represented eosinophilic cellulitis...
January 15, 2018: Dermatology Online Journal
https://www.readbyqxmd.com/read/29469762/anaplastic-large-cell-lymphoma-localized-to-the-left-breast-years-after-radiotherapy-for-breast-cancer
#9
Michelle S Min, Ali Al-Haseni, Farah Succaria, Lynne Goldberg, Adam Lerner, Debjani Sahni
Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma that can involve the skin primarily or secondarily. Our case describes an unusual presentation of eruptive tumors localized to the leftbreast region several years following breast cancer surgery and radiation for carcinoma of the breast. This report highlights the challenges in reachingthe diagnosis of an aggressive systemic lymphoma presenting on the skin.
January 15, 2018: Dermatology Online Journal
https://www.readbyqxmd.com/read/29469175/presence-of-autoimmune-disease-affects-not-only-risk-but-also-survival-in-patients-with-b-cell-non-hodgkin-lymphoma
#10
Geffen Kleinstern, Mor Averbuch, Rania Abu Seir, Riki Perlman, Dina Ben Yehuda, Ora Paltiel
Although autoimmune diseases (AIDs) are known to predispose to non-Hodgkin lymphoma (NHL), their association with NHL prognosis has rarely been investigated. We examined associations between autoimmunity and B-cell NHL onset by comparing AID history (determined by self-report and medication review and supplemented by chart review where possible) among 435 adult B-NHL patients in Hadassah-Hebrew University Medical Center, diagnosed 2009-2014, and 414 age-and-sex frequency-matched controls. We examined AIDs as a whole, B- and T-cell-mediated AIDs, and autoimmune thyroid diseases...
February 22, 2018: Hematological Oncology
https://www.readbyqxmd.com/read/29468647/brentuximab-vedotin-prior-to-allogeneic-stem-cell-transplantation-in-hodgkin-lymphoma-a-report-from-the-ebmt-lymphoma-working-party
#11
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, Mohamad Mohty, Luca Castagna, Karl S Peggs, Didier Blaise, Boris Afanasyev, José L Diez-Martin, Jorge Sierra, Adrian Bloor, Carmen Martinez, Stephen Robinson, Ram Malladi, Jean El-Cheikh, Paolo Corradini, Silvia Montoto, Peter Dreger, Anna Sureda
Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate. Preliminary data suggest that BV might improve outcomes after allogeneic stem cell transplantation (SCT) for Hodgkin lymphoma (HL) when used as pre-transplant salvage therapy. Between 2010 and 2014, 428 adult patients underwent an allogeneic SCT for classical HL at participating centres of the European Society for Blood and Marrow Transplantation. We compared the outcomes of 210 patients who received BV prior to allogeneic SCT with that of 218 patients who did not receive BV...
February 22, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29468437/young-adults-diagnosed-with-hodgkin-lymphoma-are-at-risk-of-relapsing-late-a-comprehensive-analysis-of-late-relapse-in-hodgkin-lymphoma
#12
László Pinczés, Zsófia Miltényi, Árpád Illés
PURPOSE: Majority of relapses in Hodgkin lymphoma (HL) occur within 3 years after initial treatment, late relapses (LR), happening 5 or more years after first diagnosis is rare events. Neither clinical characteristics, risk factors, nor optimal treatment is well described for LR patients. Our aim was to provide a comprehensive analysis on the LR of HL to outline a patient population at risk of relapsing late. PATIENTS AND METHODS: 637 HL patients were treated at the University of Debrecen between 1981 and 2010...
February 21, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29467338/tcr-mimic-bispecific-antibodies-targeting-lmp2a-show-potent-activity-against-ebv-malignancies
#13
Mahiuddin Ahmed, Andres Lopez-Albaitero, Dmitry Pankov, Brian H Santich, Hong Liu, Su Yan, Jingyi Xiang, Pei Wang, Aisha N Hasan, Annamalai Selvakumar, Richard J O'Reilly, Cheng Liu, Nai-Kong V Cheung
EBV infection is associated with a number of malignancies of clinical unmet need, including Hodgkin lymphoma, nasopharyngeal carcinoma, gastric cancer, and posttransplant lymphoproliferative disease (PTLD), all of which express the EBV protein latent membrane protein 2A (LMP2A), an antigen that is difficult to target by conventional antibody approaches. To overcome this, we utilized phage display technology and a structure-guided selection strategy to generate human T cell receptor-like (TCR-like) monoclonal antibodies with exquisite specificity for the LMP2A-derived nonamer peptide, C426LGGLLTMV434 (CLG), as presented on HLA-A*02:01...
February 22, 2018: JCI Insight
https://www.readbyqxmd.com/read/29467311/epstein-barr-virus-nuclear-antigen-leader-protein-co-activates-ep300
#14
Chong Wang, Hufeng Zhou, Yong Xue, Jun Liang, Yohei Narita, Catherine Gerdt, Amy Y Zheng, Runsheng Jiang, Stephen Trudeau, Chih-Wen Peng, Benjamin Gewurz, Bo Zhao
Epstein-Barr virus nuclear antigen (EBNA) leader protein (EBNALP) is one of the first viral genes expressed upon B-cell infection. EBNALP is essential for EBV-mediated B cell immortalization. EBNALP is thought to function primarily by co-activaing EBNA2-mediated transcription. Chromatin immune precipitation followed by deep-sequencing (ChIP-seq) studies highlight that EBNALP frequently co-occupies DNA sites with host cell transcription factors (TFs), in particular EP300, implicating a broader role in transcription regulation...
February 21, 2018: Journal of Virology
https://www.readbyqxmd.com/read/29465563/non-hodgkin-lymphoma-diagnostic-and-prognostic-particularities-in-children-a-series-of-case-reports-and-a-review-of-the-literature-care-compliant
#15
Cristina Oana Mărginean, Lorena Elena Meliţ, Emoke Horvath, Horea Gozar, Mihaela Ioana Chinceşan
RATIONALE: Non-Hodgkin lymphoma remains an unpredictable condition in pediatric patients. PATIENT CONCERNS: Our first case describes an 8-year-old boy with a history of iron deficiency anemia, admitted in our clinic for recurrent abdominal pain, weight loss, loss of appetite, diarrheic stools, and fever. The second case also describes an 8-year-old boy admitted for abdominal pain and vomiting. The 3rd case refers to a 4 years and 10 months old boy admitted in our clinic with abdominal pain and loss of appetite, who was initially admitted in the Pediatrics Surgery Clinic with the suspicion of appendicitis...
February 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29465366/cancer-development-in-korean-patients-with-anca-associated-vasculitis-a-single-centre-study
#16
Juyoung Yoo, Sung Soo Ahn, Seung Min Jung, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee
OBJECTIVES: We investigated the incidence rate and type of cancer, and furthermore, estimated the standardised incidence ratios (SIRs) of cancer in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in Korea. METHODS: We retrospectively included 150 patients with AAV [81 patients with microscopic polyangiitis (MPA), 38 with granulomatosis with polyangiitis (GPA) and 31 patients with eosinophilic GPA (EGPA)], and reviewed their medical records...
February 14, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29463935/a20-tnfaip3-alterations-in-primary-intestinal-diffuse-large-b-cell-lymphoma
#17
Masayoshi Fujii, Katsuyoshi Takata, Shih-Sung Chuang, Tomoko Miyata-Takata, Midori Ando, Yasuharu Sato, Tadashi Yoshino
The gastrointestinal (GI) tract is the most frequently involved site of extranodal non-Hodgkin lymphomas, and diffuse large B-cell lymphoma (DLBCL) is the most common subtype occurring in the GI tract. TNFAIP3 (A20) genetic alterations were reported to be involved in DLBCL's pathogenesis and a portion of GI-DLBCL cases harbor this alteration. However, the frequency and clinicopathological relations focusing on small and large intestinal DLBCL are unclear. Here, we examined A20 deletion and protein expression and analyzed the clinicopathological features of 52 cases of primary intestinal DLBCL...
February 2018: Acta Medica Okayama
https://www.readbyqxmd.com/read/29463178/interim-fdg-pet-ct-in-hodgkin-lymphoma-what-are-we-actually-looking-at
#18
Hugo J A Adams, Thomas C Kwee
No abstract text is available yet for this article.
February 20, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29461329/cancer-in-adolescents-and-young-adults-living-with-hiv
#19
Julia Bohlius, Caroline Foster, Gita Naidu, Mazvita Sengayi, Anna Turkova
PURPOSE OF REVIEW: Adults living with HIV have an increased risk of malignancy yet there is little data for adolescents and young adults. We reviewed recently published cancer epidemiology, treatment, and outcome data for adolescents and young adults living with HIV (AYALHIV) aged 10 to less than 25 years between 2016 and 2017. RECENT FINDINGS: AYALHIV are at increased risk of developing cancer compared to their uninfected peers. Kaposi sarcoma and non-Hodgkin lymphoma occur most frequently with variation by geographical region...
February 15, 2018: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/29460427/alcohol-consumption-and-risk-of-hematological-malignancies-a-meta-analysis-of-prospective-studies
#20
Theodora Psaltopoulou, Theodoros N Sergentanis, Ioannis Ntanasis-Stathopoulos, Ioannis-Georgios Tzanninis, Diamantis I Tsilimigras, Meletios A Dimopoulos
Current convincing evidence suggests that alcohol intake increases the risk of several carcinomas, which might subsequently lead to a recommendation towards limiting alcohol consumption. However, there are accumulating data worth meta-analyzing that show a different effect on the risk of hematological malignancies. Eligible cohort studies were sought in PubMed database up to August 31, 2016. Separate analyses were performed by subtype of hematological malignancy (non-Hodgkin lymphoma [NHL] and subtypes, Hodgkin lymphoma [HL], leukemia and subtypes), time status (ever, current, former), level of consumption (light, moderate, heavy), alcoholic beverage (total alcohol, beer, liquor, wine), and gender...
February 20, 2018: International Journal of Cancer. Journal International du Cancer
keyword
keyword
27364
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"